Pazopanib in treatment of hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2024.10.014 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Magdalena D Lewandowska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, USA. Electronic address: mlewandowska@IHTC.org. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Pyrimidines, Gastrointestinal Hemorrhage, Sulfonamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is a bleeding disorder characterized by arteriovenous malformations, commonly presenting with epistaxis and gastrointestinal (GI) bleeding. Bleeding symptoms may be difficult to manage and may become life-threatening, with many patients developing dependence on parenteral iron and/or blood transfusion. There is a growing body of evidence that antiangiogenic therapies may be effective in management of bleeding symptoms, presumably targeting pathogenic HHT pathways such as vascular endothelial growth factor receptor. OBJECTIVES: To report single-center, retrospective real-world use of pazopanib, an orally administered tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors, in 6 patients with HHT-associated epistaxis and/or GI bleeding. METHODS: A retrospective observational analysis was performed to assess the safety/efficacy of pazopanib use in patients with confirmed HHT-associated epistaxis and/or GI bleeding between January 1, 2019, and June 14, 2023. The Indiana Hemophilia and Thrombosis institutional electronic medical record was queried for HHT patients who were treated with pazopanib for ≥3 months. Patient data were obtained from patient documentation, physician/nursing notes, and on-call documentation. Institutional review board approval was obtained for data pull as an exempt study. RESULTS: Our observations on the real-world use of pazopanib in 6 HHT patients with moderate-to-severe bleeding showed improvement in hemoglobin levels, with reduction in iron infusions and red blood cell transfusion requirement. CONCLUSION: Pazopanib may be a reasonable option for patients with HHT with epistaxis or gastrointestinal bleeding that are refractory to standard treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, USA. Electronic address: mlewandowska@IHTC.org.
- Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, USA.
Zitieren
APA
Lewandowska, M. D., Gordon, S., Betbadal, A., & Shapiro, A. D. (2025). Pazopanib in treatment of hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.10.014
Vancouver
Lewandowska MD, Gordon S, Betbadal A, Shapiro AD. Pazopanib in treatment of hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.10.014
BibTeX
@article{Lewandowska2025,
author = {Lewandowska, Magdalena D and Gordon, Shelby and Betbadal, Anthony and Shapiro, Amy D},
title = {Pazopanib in treatment of hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2024.10.014}
}
EUVIMED